Text this: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

 __   _      ___      _____     ______  __    __  
| || | ||   / _ \\   |__  //   /_   _// \ \\ / // 
| '--' ||  | / \ ||    / //     -| ||-   \ \/ //  
| .--. ||  | \_/ ||   / //__    _| ||_    \  //   
|_|| |_||   \___//   /_____||  /_____//    \//    
`-`  `-`    `---`    `-----`   `-----`      `